Lataa...
RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src
Overexpression of EGFR is commonly seen in gastric cancer (GC). However, patients with GC show resistance to anti-EGFR treatments. RAS mutations are rare in GC and cannot explain de novo resistance to EGFR treatments. Therefore, it is particularly important to explore the mechanisms of resistance to...
Tallennettuna:
| Julkaisussa: | Onco Targets Ther |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5229171/ https://ncbi.nlm.nih.gov/pubmed/28123301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S110918 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|